Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapy.
about
Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney diseaseThe proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction.Tubular obstruction leads to progressive proximal tubular injury and atubular glomeruli in polycystic kidney diseaseThe importance of total kidney volume in evaluating progression of polycystic kidney diseaseThe cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation.Mesenchymal Stromal Cells Improve Renovascular Function in Polycystic Kidney Disease.Magnetic resonance microscopy of renal and biliary abnormalities in excised tissues from a mouse model of autosomal recessive polycystic kidney diseaseExploitation of the Polymeric Immunoglobulin Receptor for Antibody Targeting to Renal Cyst Lumens in Polycystic Kidney DiseaseRenal cyst growth is the main determinant for hypertension and concentrating deficit in Pkd1-deficient mice.Novel insights into TRPV4 function in the kidney.TRPV4 dysfunction promotes renal cystogenesis in autosomal recessive polycystic kidney disease.Functional and therapeutic importance of purinergic signaling in polycystic kidney disease.Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.Regulation of KCNQ1/KCNE1 by β-catenin.Identification of Targets of Interleukin-13 and Signal Transducer and Activator of Transcription-6 (STAT6) Signaling in Polycystic Kidney Disease.Deficient transient receptor potential vanilloid type 4 function contributes to compromised [Ca2+]i homeostasis in human autosomal-dominant polycystic kidney disease cells.The polymorphism of the ACE gene affects left ventricular hypertrophy and causes disturbances in left ventricular systolic/diastolic function in patients with autosomal dominant polycystic kidney disease.
P2860
Q27011660-043DE380-2595-4488-AE15-C63247F2D791Q30276784-88E6D88E-923C-4B6B-A48E-21E48E528D5FQ30384348-D8FE5245-2745-4ED8-9DF4-B0FC8AD91327Q33873107-C43C8430-FA06-430F-A089-0AA55430BEECQ33974670-B8055B40-0C29-49C7-9D3A-168CB580ECAEQ35287851-2AB60019-311B-41F2-A195-7A1E04B04843Q35759778-D0A56F24-12D2-4745-B5C5-9B35A333FD85Q35860685-019C9948-ABF8-4748-9E92-FBCF01D1D3CCQ35878445-A689CDDA-3880-465D-B109-AF358EE8E741Q36581884-7DCB9476-1D7D-40FE-B923-3217BC4032A9Q36719236-EFC36DC5-A821-4F5B-A1E4-D20BB5B53906Q38961131-48082607-01E6-4334-AB2A-CA1221A5C66AQ41661686-176B4A8B-A218-4276-81ED-6097EFDD0DA8Q48648940-03271775-6D1F-4D1A-975B-67167FC6B0C6Q50420556-5A14F10C-B2F5-4B54-A575-9899EC4810E3Q52689816-E553B96D-AD24-4163-B73F-D3A2EA2C7935Q55709403-655B1D54-8A7E-4E8A-A40F-230CE58F1686
P2860
Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Polycystic kidney disease in 2 ...... cystic kidney disease therapy.
@en
Polycystic kidney disease in 2 ...... cystic kidney disease therapy.
@nl
type
label
Polycystic kidney disease in 2 ...... cystic kidney disease therapy.
@en
Polycystic kidney disease in 2 ...... cystic kidney disease therapy.
@nl
prefLabel
Polycystic kidney disease in 2 ...... cystic kidney disease therapy.
@en
Polycystic kidney disease in 2 ...... cystic kidney disease therapy.
@nl
P2860
P356
P1476
Polycystic kidney disease in 2 ...... cystic kidney disease therapy.
@en
P2093
Peter C Harris
Vicente E Torres
P2860
P2888
P356
10.1038/NRNEPH.2011.196
P407
P577
2011-12-13T00:00:00Z